Bank Of New York Mellon Corp Apellis Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$46.59 - $66.96 $18.3 Million - $26.3 Million	392,396 New	392,396 $25.9 Billion
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $17.5 Million - $24.7 Million	405,039 New	405,039 $20.9 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $2.7 Million - $4.2 Million	60,309 Added 17.32%	408,459 $27.9 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $1.15 Million - $1.93 Million	32,670 Added 10.36%	348,150 $15.7 Million
Q1 2022 May 11, 2022	BUY	$35.46 - $54.12 $612,997 - $935,572	17,287 Added 5.8%	315,480 $16 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $882,514 - $1.41 Million	28,709 Added 10.65%	298,193 $14.1 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $234,118 - $520,727	7,456 Added 2.85%	269,484 $8.88 Million
Q2 2021 Aug 11, 2021	BUY	$40.9 - $64.9 $1.43 Million - $2.26 Million	34,894 Added 15.36%	262,028 $16.6 Million
Q1 2021 May 13, 2021	SELL	$40.8 - $57.39 $1.1 Million - $1.55 Million	-27,073 Reduced 10.65%	227,134 $9.75 Million
Q4 2020 Feb 09, 2021	BUY	$30.79 - $57.2 $487,929 - $906,448	15,847 Added 6.65%	254,207 $14.5 Million
Q3 2020 Nov 12, 2020	SELL	$25.89 - $33.65 $136,699 - $177,672	-5,280 Reduced 2.17%	238,360 $7.19 Million
Q2 2020 Aug 12, 2020	BUY	$24.8 - $38.49 $89,800 - $139,372	3,621 Added 1.51%	243,640 $7.96 Million
Q1 2020 May 06, 2020	BUY	$17.91 - $44.33 $784,816 - $1.94 Million	43,820 Added 22.33%	240,019 $6.43 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $134,213 - $187,048	6,073 Added 3.19%	196,199 $6.01 Million
Q3 2019 Nov 07, 2019	SELL	$24.09 - $32.18 $239,237 - $319,579	-9,931 Reduced 4.96%	190,126 $4.58 Million
Q2 2019 Aug 12, 2019	BUY	$18.0 - $25.34 $547,290 - $770,462	30,405 Added 17.92%	200,057 $5.07 Million
Q1 2019 May 14, 2019	BUY	$12.81 - $19.82 $216,898 - $335,592	16,932 Added 11.09%	169,652 $3.31 Million
Q4 2018 Feb 11, 2019	BUY	$11.47 - $18.71 $113,920 - $185,827	9,932 Added 6.96%	152,720 $2.02 Million
Q3 2018 Nov 09, 2018	BUY	$16.57 - $21.03 $258,839 - $328,509	15,621 Added 12.28%	142,788 $0
Q2 2018 Aug 06, 2018	BUY	$19.63 - $30.0 $1.81 Million - $2.77 Million	92,280 Added 264.51%	127,167 $2.8 Million
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $220,251 - $409,060	15,721 Added 82.03%	34,887 $771,000
Q4 2017 Feb 09, 2018	BUY	$12.71 - $21.7 $243,599 - $415,902	19,166	19,166 $416,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$516 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$394 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$368 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$325 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$192 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account